Aptevo Therapeutics Inc. - 8-K Filing

Aptevo Therapeutics reports substantial reduction in infusion-related reactions for mipletamig via refined priming-dose regimen. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $APVO

Read the full article at SEC EDGAR

More Regulatory news